EGF and Erythema: In mice, both EGF and pimecrolimus—a topical calcineurin inhibitor—groups showed reduced erythema, inflammation, and expression of thymic stromal lymphopoietin (TSLP), a cytokine that plays a role in the pathogenesis of AD.